SK35196A3 - Use of thiazolidinedione derivative and related agents - Google Patents

Use of thiazolidinedione derivative and related agents Download PDF

Info

Publication number
SK35196A3
SK35196A3 SK351-96A SK35196A SK35196A3 SK 35196 A3 SK35196 A3 SK 35196A3 SK 35196 A SK35196 A SK 35196A SK 35196 A3 SK35196 A3 SK 35196A3
Authority
SK
Slovakia
Prior art keywords
group
alkyl
formula
atom
substituted
Prior art date
Application number
SK351-96A
Other languages
English (en)
Slovak (sk)
Inventor
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22401599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK35196(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SK35196A3 publication Critical patent/SK35196A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK351-96A 1993-09-15 1994-09-09 Use of thiazolidinedione derivative and related agents SK35196A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08/292,585 US5457109A (en) 1993-09-15 1994-08-23 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PCT/US1994/010187 WO1995007697A2 (en) 1993-09-15 1994-09-09 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
SK35196A3 true SK35196A3 (en) 1997-12-10

Family

ID=22401599

Family Applications (1)

Application Number Title Priority Date Filing Date
SK351-96A SK35196A3 (en) 1993-09-15 1994-09-09 Use of thiazolidinedione derivative and related agents

Country Status (22)

Country Link
US (3) US5478852C1 (zh)
EP (2) EP0719143B1 (zh)
JP (1) JPH09502722A (zh)
KR (2) KR960704546A (zh)
CN (1) CN1106195C (zh)
AT (2) ATE198045T1 (zh)
AU (1) AU678291B2 (zh)
CA (1) CA2168751A1 (zh)
CZ (3) CZ72296A3 (zh)
DE (3) DE69426421T2 (zh)
DK (2) DK0719143T3 (zh)
ES (2) ES2154685T3 (zh)
GR (1) GR3035430T3 (zh)
HK (1) HK1085134A1 (zh)
HU (1) HUT75873A (zh)
NO (1) NO961052D0 (zh)
NZ (2) NZ336689A (zh)
PT (3) PT719143E (zh)
RU (1) RU2281094C2 (zh)
SG (1) SG67900A1 (zh)
SK (1) SK35196A3 (zh)
WO (1) WO1995007697A2 (zh)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046202A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of insulin resistance
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
CA2157032C (en) * 1993-12-27 1999-09-28 Hisashi Shinkai Isoxazolidinedione derivative and use thereof
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
ATE235476T1 (de) * 1994-08-10 2003-04-15 Takeda Chemical Industries Ltd Thiazolidindione derivate, ihre herstellung und verwendung
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5985884A (en) * 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
DE69738809D1 (de) * 1996-11-08 2008-08-14 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
AU2809797A (en) * 1997-01-15 1998-08-07 Centre National De La Recherche Scientifique Centre De Recherche Sur L'endocrinologie Moleculaire Et Le Developpement Respiration uncoupling protein
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
WO1998042340A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
AU8539298A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6265401B1 (en) * 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
AU1172999A (en) 1997-11-19 1999-06-07 Takeda Chemical Industries Ltd. Novel apoptosis inhibitors
JP2001526061A (ja) * 1997-12-23 2001-12-18 イーライ・リリー・アンド・カンパニー β−リポトロピンおよびその使用
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000025781A1 (en) * 1998-10-29 2000-05-11 Board Of Regents, The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
KR100643833B1 (ko) 1998-11-12 2006-11-10 스미스클라인비이참피이엘시이 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물
AR023700A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US6326396B1 (en) 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
OA11871A (en) * 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
ES2203453T3 (es) * 1999-04-23 2004-04-16 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bentil)tiazolidina-2,4-diona.
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
JP2003519154A (ja) * 1999-12-22 2003-06-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なビスアミダートホスホネートプロドラッグ
AU3982601A (en) * 2000-02-23 2001-09-03 Orentreich Foundation For The Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
US6464959B1 (en) * 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
WO2001094410A1 (en) * 2000-06-08 2001-12-13 Metcon Medicin Ab Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
SE0002189D0 (sv) 2000-06-09 2000-06-09 Metcon Medicin Ab New method and assay
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
AU2003217820A1 (en) * 2002-02-28 2003-09-16 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20040033954A1 (en) * 2002-08-15 2004-02-19 Sleeman Mark W. Therapeutic method for combined use of modified CNTF and thiadolidinedione
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
CN100344618C (zh) 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
WO2008147454A1 (en) * 2006-11-16 2008-12-04 Case Western Reserve University Selective inhibitors of translesion dna replication
WO2006101911A1 (en) 2005-03-16 2006-09-28 Case Western Reserve University Selective inhibitors of translesion dna replication
US20080207711A1 (en) * 2007-02-28 2008-08-28 Rong Li Method for treating an ID2-related disorder
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
EP2825546B1 (en) 2011-09-01 2017-07-12 Case Western Reserve University Non-natural nucleosides as theranostic agents
US9192766B2 (en) 2011-12-02 2015-11-24 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and devices for treatment of polycystic kidney disease
AU2013230781B2 (en) * 2012-03-08 2015-12-03 Medtronic Af Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2014068397A1 (en) 2012-11-05 2014-05-08 Commissariat A L'energie Atomique Et Aux Energies Atlternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
US9821173B2 (en) 2013-02-08 2017-11-21 Case Western Reserve University Anti-cancer agents and methods of use
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
EP3297625B1 (en) 2015-05-22 2022-07-06 Sulfateq B.V. Compound for the prophylaxis or treatment of diabetic nephropathy or diabetic kidney disease
GB201518979D0 (en) * 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation
CN115536653B (zh) * 2022-09-30 2024-08-13 五邑大学 一种色酮噻唑二酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396392A (en) * 1977-02-01 1978-08-23 Kakenyaku Kako Kk Active substance for increasing secretion of insulin
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
WO1991012003A1 (en) * 1990-02-09 1991-08-22 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ATE142631T1 (de) * 1991-06-25 1996-09-15 Pfizer Thiazolidindione als hypoglykämische wirkstoffe
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
CZ282296A3 (cs) 1998-01-14
CZ72296A3 (en) 1996-10-16
AU678291B2 (en) 1997-05-22
DE69435039D1 (de) 2007-12-13
RU2281094C2 (ru) 2006-08-10
AU7724994A (en) 1995-04-03
DK1637138T3 (da) 2011-05-23
EP1637138A2 (en) 2006-03-22
PT719143E (pt) 2001-03-30
HUT75873A (en) 1997-05-28
EP1637138A3 (en) 2006-06-28
CN1106195C (zh) 2003-04-23
WO1995007697A2 (en) 1995-03-23
PT719140E (pt) 2008-01-17
EP0719143B1 (en) 2000-12-13
US5457109A (en) 1995-10-10
EP1637138B1 (en) 2010-12-01
DE69426421T2 (de) 2001-04-19
DE69435328D1 (de) 2011-01-13
GR3035430T3 (en) 2001-05-31
ATE489952T1 (de) 2010-12-15
WO1995007697A3 (en) 1995-05-11
US5478852C1 (en) 2001-03-13
ES2356316T3 (es) 2011-04-06
ES2154685T3 (es) 2001-04-16
NO961052L (no) 1996-03-14
EP0719143A1 (en) 1996-07-03
CA2168751A1 (en) 1995-03-23
NO961052D0 (no) 1996-03-14
US5478852A (en) 1995-12-26
DK0719143T3 (da) 2001-03-05
HK1085134A1 (en) 2006-08-18
CZ282396A3 (cs) 1998-01-14
HU9600674D0 (en) 1996-05-28
DE69435039T2 (de) 2008-08-14
JPH09502722A (ja) 1997-03-18
CZ283208B6 (cs) 1998-01-14
NZ336689A (en) 2000-11-24
NZ273806A (en) 1999-08-30
CN1131391A (zh) 1996-09-18
US5602133A (en) 1997-02-11
KR960704546A (ko) 1996-10-09
KR960704544A (ko) 1996-10-09
CZ283207B6 (cs) 1998-01-14
SG67900A1 (en) 1999-10-19
PT1637138E (pt) 2011-02-22
DE69426421D1 (de) 2001-01-18
ATE198045T1 (de) 2000-12-15

Similar Documents

Publication Publication Date Title
SK35196A3 (en) Use of thiazolidinedione derivative and related agents
US6046222A (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP3081245B2 (ja) Ｎｉｄｄｍの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
US5708012A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
AU731690B2 (en) Use of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)-ethoxy)benzyl) 2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
US6046202A (en) Use of thiazolidinedione derivatives in the treatment of insulin resistance
AU754479B2 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
MXPA99008704A (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
AU750615B2 (en) Use of thiazolidinediones to prevent or delay onset of NIDDM
KR100697097B1 (ko) 당뇨병 예방 또는 치료용 약학 조성물
MXPA99008411A (en) Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
NZ522885A (en) Use of rosiglitazone in the treatment of polycystic ovary syndrome ( PCOS ) and gestational diabetes ( GDM )
MXPA97009958A (en) A method to reduce the amount of exogenous insulin administered to a patient with diabetes melitus dependent of insul
AU5257699A (en) Use of thiazolidinediones to prevent or delay onset of NIDDM